

## Special Issue

# New Generation Imaging in Oncology

### Message from the Guest Editor

The introduction of molecular imaging, namely positron emission tomography (PET) imaging in oncology, has already changed the clinical outcomes and therapeutic management of oncological patients. Several PET radiopharmaceuticals have been proposed in oncology over the last decade, and these diagnostic techniques are now currently placed under the umbrella term new generation imaging. The most successful approaches proposed for PET imaging, other than FDG-PET, have been receptor tracers targeting the somatostatin receptors (SSRs) and the prostate-specific membrane antigen (PSMA), proposed to investigate neuroendocrine tumours and prostate cancer, respectively. Both of these in vivo biomarkers can be used both for diagnostic (PET imaging) and therapeutic (radioligand therapy) purposes, and are currently considered the cornerstones of the theranostic approach. The application of radiomics in PET imaging is an emerging field. Radiomics is defined as the high-throughput extraction of quantitative features from medical images. This approach provides high-dimensional data describing properties of shape and texture of tumours captured in different diagnostic procedures.

---

### Guest Editor

Dr. Francesco Ceci

Department of Medical Sciences, Università degli Studi di Torino, Turin, Italy

---

### Deadline for manuscript submissions

closed (30 November 2020)



## Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/48111](https://mdpi.com/si/48111)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPUS / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).